PD-1 Drug
Nov 05, 2026
After KEYTRUDA: How PD-1 and PD-L1 Inhibitors Are Being Redesigned for a Post-Patent Era
Summary The PD-1 and PD-L1 inhibitors list now spans a dozen or more approved drugs. Clinical efficacy is broadly similar across them, so winners are decided by trial breadth, indication coverage, and convenience. Subcutaneous atezolizumab (2024), nivolumab (2024), and pembrolizumab (Keytruda Qlex, September...
Read More...
Mar 07, 2025
TEVIMBRA’s Winning Streak — BeiGene Secures New Indication for PD-1 Drug
On March 3, 2025, BeiGene secured another approval for its anti-PD-1 antibody, TEVIMBRA, as the FDA granted clearance for its use in combination with platinum-based chemotherapy as a first-line treatment for adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1....
Read More...
-Agonist.png "Toll-like Receptors Agonist")
